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There are limited data on the impact of antiretroviral therapy (ART) on population-level adult mortality in
sub-Saharan Africa. We analysed data for 2000–14 from the Rakai Community Cohort Study (RCCS) in
Uganda, where free ART was scaled up after 2004. Using non-parametric and parametric (Weibull)
survival analysis, we estimated trends in average person-years lived between exact ages 15 and 50, per
capita life-years lost to HIV, and the mortality hazards of people living with HIV (PLHIV). Between
2000 and 2014, average adult life-years lived before age 50 increased significantly, from 26.4 to
33.5 years for all women and from 28.6 to 33.8 years for all men. As of 2014, life-years lost to HIV had
declined significantly, to 1.3 years among women and 0.4 years among men. Following the roll-out of
ART, mortality reductions among PLHIV were initially larger in women than men, but this is no
longer the case.
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Introduction
Before the introduction of antiretroviral therapy
(ART), HIV/AIDS was a leading cause of death
among adults aged 15–49 years in the rural Rakai dis-
trict, Uganda. Among adults with HIV, mortality in
the 1990s was around 132.6 deaths per 1,000 (Serwadda
et al. 1985; Sewankambo et al. 1994, 2000). Many clini-
cal cohort studies have demonstrated the impact of
ART on adult mortality in ‘people living with HIV’
(referred to hereafter as PLHIV) who are enrolled in
treatment programmes (Herbst and Cooke 2008; Brin-
khof et al. 2009; Mills, Bakanda, Birungi, Chan, Ford,
et al. 2011), but have not assessed the impact of ART
at a population level. Demographic surveillance data
are needed to estimate population-level effects of
ART because such data include PLHIV who are not
in care. A number of studies have documented the
impact of ART on population-level mortality trends
in eastern and southern Africa (Jahn et al. 2008;
Herbst et al. 2009; Kasamba et al. 2012).
Some of these studies have estimated the life-years
gained following the scale-up of ART and the
number of life-years that remain lost to HIV (Bor
et al. 2013; Asiki et al. 2016; Price et al. 2017; Reniers
et al. 2017). These studies report better outcomes for
women than men due to higher ART use (Muula
et al. 2007; Druyts et al. 2013; Staveteig et al. 2013),
earlier treatment initiation, and lower attrition and
mortality while on ART among women (May et al.
2010; Hawkins et al. 2011; Mills, Bakanda, Birungi,
Chan, Hogg, et al. 2011; Cornell et al. 2012; Auld
et al. 2013; Druyts et al. 2013).
In this study we use data from the Rakai Commu-
nity Cohort Study (RCCS), a demographic and HIV
surveillance cohort study in the rural Rakai District
of south-central Uganda, to estimate the popu-
lation-wide impact of ART on adult mortality.
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Methods
Since 1994 the Rakai Health Sciences Program
(RHSP) has conducted an open, community-based
cohort study, the RCCS. All households in 50 com-
munities were enumerated and, within one month,
consenting individuals aged 15–49 years were
enrolled in an HIV survey. The design and conduct
of the RCCS have been described elsewhere
(Wawer et al. 1998, 1999). In this analysis, we
include 30 communities that were consistently fol-
lowed from 2000 to 2014.
Information from the household census was used
to update the residency and vital status of household
members, and the individual interviews were used to
elicit greater detail on the risk factors for a variety of
health outcomes, including HIV. Survey participants
provided a venous blood sample for HIV detection
using two enzyme immunoassays, with western blot
or polymerase chain reaction confirmation, or both.
To allocate exposure time to HIV status categories,
we classified person-time before the first recorded
HIV test as ‘HIV status unknown’. Person-time fol-
lowing a positive HIV test remained ‘HIV-positive’
for the duration until censoring by loss to follow-
up, end of study, or death. Exposure time between
two negative tests was counted as ‘HIV-negative’,
and the time following an individual’s last negative
test was also considered HIV-negative for an esti-
mated duration of time based on the probability
that 95 per cent of their age group remained unin-
fected, given sex-specific HIV incidence rates.
Ethical considerations
Before enrolment into the RCCS, all adult partici-
pants (aged 18–49) provided written informed
consent. Adolescents (aged 15–17) provided assent
and their parents or guardians provided consent on
their behalf. The RCCS was approved by the
Uganda Virus Research Institute’s Science and
Ethics Committee (currently the Research Ethics
Committee), the Uganda National Council for
Science and Technology, Institutional Review
Boards (IRBs) at Johns Hopkins and Columbia uni-
versities, andWestern IRB in the United States (US).
HIV care programme
Until 2004, there was limited access to ART in
Uganda (Wendo 2004). In June 2004, with funding
from the US President’s Emergency Plan for AIDS
Relief (PEPFAR), RHSP started to provide free
HIV treatment in Rakai district in accordance with
World Health Organization (WHO) ‘CD4’ criteria
for treatment initiation. Through record linkage
with RHSP treatment facilities, we ascertained the
treatment status of RCCS participants living with
HIV using unique identifiers. However, there are
other medical services in the study area whose data
could not be linked to the RCCS. The RHSP had pro-
vided HIV care to a total of 20,909 HIV clients in the
district as of December 2014. Of these, 7,436 were
RCCS participants (around 52 per cent of the HIV-
positive RCCS participants), of which 6,618
(around 89 per cent) were known to be on ART as
of December 2014. Enrolment into HIV care and
the ART programme is based on the WHOARTeli-
gibility criteria and the Ugandan National Antiretro-
viral Treatment Guidelines (Katabira et al. 2009). In
this analysis, we distinguish between the ‘pre-ART
period’ (January 2000–May 2004) and the ‘ART
period’ (June 2004–December 2014).
Statistical analysis
We estimated person-years lived as the area under
the Kaplan–Meier survival curve between exact
ages 15 and 50, by calendar year, HIV status, and
sex (Kalbfleisch and Prentice 2002). This measure,
sometimes referred to as partial life expectancy
(Hickman and Estell 1969), can be interpreted as
the population-average number of years that a 15-
year-old lives up to their 50th birthday under the pre-
vailing mortality conditions. The maximum value of
35 years would be reached if there were no mortality
in the age range under consideration (Kaplan and
Meier 1958). We used the measure of years lived
between 15 and 50 instead of adult life expectancy
because individuals in the RCCS are not followed
beyond age 50. Life-years lived in adulthood is a
useful measure to track the impact of ART on HIV-
associated mortality, as it is independent of the popu-
lation age structure. We also estimated the number of
life-years lost to HIV. This was computed as the
difference between the life-years lived by known
HIV-negative individuals and the life-years lived by
the whole population. In other words, the years
lived by HIV-negative individuals serves as a bench-
mark, and the shortfall in the population-average
number of years lived quantifies the residual
burden of HIV mortality in this population (Kalb-
fleisch and Prentice 2002; Klein and Moeschberger
2003; Kleinbaum and Klein 2012). Percentile-based
confidence bounds for the number of life-years
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lived and lost were obtained via bootstrapping with
1,000 replications. A comparable approach has
been used in other studies (Bor et al. 2013; Asiki
et al. 2016; Price et al. 2017; Reniers et al. 2017).
We next examined mortality trends among PLHIV
by treatment status, using parametric survival analysis
to model the mortality hazards among PLHIV, with
age as the measure of time. The Weibull model was
chosen over other models on the basis of model fit,
and it yielded similar estimates of hazard ratios to
those obtained with a semi-parametric model. We dis-
aggregated survival analyses into the pre-ART and
ART periods, and by treatment status, to differentiate
PLHIV who had never initiated ART from those who
had ever started ART (even if it was interrupted or
stopped). We considered sex, calendar year, and
their interaction as covariates. Data before the intro-
duction of ART in the study communities (January
2000–May 2004) provided an estimate of baseline
(pre-ART) mortality. Given the age-dependent cov-
ariate calendar year (y(t)) and the age-independent
covariate sex (s), the mortality hazard in the pre-
ART period is estimated by:
h(t|y(t), s) = ptp–1exp{b0 + b1y(t)+ b2s+ b3s
× y(t)} (1)
where t is age and p is the Weibull shape parameter
which yields a monotonically increasing mortality
hazard for values greater than one (Kalbfleisch and
Prentice 2002; Klein and Moeschberger 2003; Klein-
baum and Klein 2012). In the ART period, the
mortality hazard is estimated as:
h(t|y(t), s)= ptp−1exp{b0+ b1(y(t)− 2003)+
+ b2(y(t)− 2008)+ + b3s+ b4s
× (y(t)− 2003)+ + b4s× (y(t)− 2008)+}
(2)
where the spline term (y(t) − 2003)+ is equal to zero if
y(t)≤ 2003, equal to y(t) − 2003 if 2004≤ y(t) < 2008,
and equal to 2008 − 2003 if y(t)≥ 2008. Similarly, the
spline term (y(t) − 2008)+ is equal to zero if y(t)≤
2008, and equal to y(t) − 2008 if y(t) > 2008. Across
all models, to demonstrate changes in calendar time
among men, linear combinations of the calendar
time (y(t)) and sex × calendar time interaction (s × y
(t)) coefficients are presented.
Results
Between 2000 and 2014 the RCCS enumerated
58,871 individuals aged 15–49, who contributed a
total of 183,581 person-years of observation (pyo)
and 1,374 deaths (Table 1). A higher number of
women (31,476) than men (27,395) participated in
the RCCS, including 3,039 women and 1,514 men
who tested HIV-positive during the study period.
The low age cut-off in part explains the relatively
small number of HIV-positive men in the data set,
because the age profile of HIV-positive men is
usually older than that of HIV-positive women
(Gregson et al. 2002). Among PLHIV, at least 708
women (23.3 per cent) and 311 men (20.5 per cent)
Table 1 Person-years, deaths, and mortality rates by sex and treatment period, ages 15–49, Uganda 2000–14
Variables
Pre-ART period (2000–03)1 ART period (2004–14)2
Male Female Male Female
Number of individuals 9,396 10,776 17,999 20,700
Number of person-years 20,924 22,822 67,403 72,432
Number of deaths 249 313 432 380
Number of deaths to HIV-positive individuals 125 224 185 193
Mortality rates (per 1,000 pyo)
Overall death rate (all-cause) 11.9
(10.5–13.5)
13.7
(12.3–15.3)
6.4
(5.8–7.0)
5.2
(4.7–5.8)
Death rate for HIV-negative individuals 3.1
(2.2–4.3)
2.3
(1.6–3.3)
3.0
(2.4–3.6)
2.2
(1.8–2.7)
Death rate for HIV-positive individuals (PLHIV) 101.0
(84.7–120.3)
100.4
(88.1–114.4)
43.9
(38.0–50.7)
24.1
(20.9–27.7)
Death rate for individuals with HIV status unknown 10.6
(8.6–13.0)
8.5
(6.6–11.1)
5.1
(4.3–6.0)
4.3
(3.5–5.2)
1The period 2000–03 includes January–May 2004.
2The period 2004–14 excludes January–May 2004.
Note: 95 per cent confidence intervals are shown in parentheses. Pyo refers to person-years of observation.
Source: Authors’ calculations from RCCS data.
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initiated ART between June 2004 and December
2014 (inclusive).
Following the roll-out of ART in 2004, the overall
death rate in adulthood decreased from 11.9 deaths
(95 per cent confidence interval (CI): 10.5–13.5) to
6.4 deaths per 1,000 pyo (95 per cent CI: 5.8–7.0)
among men, and from 13.7 deaths (95 per cent CI:
12.3–15.3) to 5.2 deaths per 1,000 pyo (95 per cent
CI: 4.7–5.8) among women. The mortality decline
among PLHIV was more pronounced among
women: adult mortality rates in HIV-positive men
declined from 101.0 (95 per cent CI: 84.7–120.3) to
43.9 deaths per 1,000 pyo (95 per cent CI: 38.0–
50.7), whereas those of HIV-positive women
declined from 100.4 (95 per cent CI: 88.1–114.4) to
24.1 deaths per 1,000 pyo (95 per cent CI: 20.9–
27.7) (Table 1). These mortality declines translated
to substantial increases in the life-years lived in adult-
hood (partial life expectancy between ages 15 and 50;
see Figure 1). The population-wide number of life-
years lived between ages 15 and 50 (Figure 1(a), all
men and women) increased by 7.1 years for
women, from 26.4 (95 per cent CI: 25.1–27.9) to
33.5 years (95 per cent CI: 32.2–34.5), and by
5.2 years for men, from 28.6 (95 per cent CI: 27.4–
29.9) to 33.8 years (95 per cent CI: 32.9–34.7). It is
worth noting that partial life expectancy had started
to increase before the roll-out of ART, in part due
to the use of prophylaxis with cotrimoxazole.
Among HIV-negative individuals there was
minimal mortality in early adulthood, and the
average number of years lived between ages 15 and
50 approached the ceiling of 35 years for both
sexes, with minimal change over time (years lived
ranged from 32.7 to 34.7 years; Figure 1(a)).
Among PLHIV (Figure 1(b)), the years lived in
adulthood increased by more than ten years for
both men and women following the introduction of
Figure 1 Life-years lived by (a) HIV-negative individuals, (b) HIV-positive individuals, and (c) individuals with
unknown HIV status, compared with the population as a whole; and (d) population-wide life-years lived and lost
to HIV; all between ages 15 and 50, by sex and calendar year, Uganda 2000–14
Source: Authors’ calculations from RCCS data.
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ART (see the 2004–14 period for women and 2004–
13 for men), but confidence intervals are wide
because of small numbers. In addition, the estimates
for PLHIVare sensitive to the timing of diagnosis or
HIV testing, which complicates their interpretation.
The increase in life-years lived for those of
unknown HIV status was similar to that seen in the
total population, which suggests that individuals
whose HIV status was unknown are not highly
selected with respect to HIV status (Figure 1(c)).
The life-years deficit, that is, the difference in the
partial life expectancy between HIV-negative indi-
viduals and the population as a whole, is a more
stable measure of the burden of HIV mortality at
the population level (Figure 1(d)). For the year
2000, this burden was estimated at 8.1 years for
women (95 per cent CI: 6.5–9.5) and 4.3 years for
men (95 per cent CI: 2.9–5.7). By 2014, the adult
life-year deficits in adulthood had almost entirely dis-
sipated, to 1.3 years (95 per cent CI: 0.3–2.5) for
women and 0.4 years (95 per cent CI: −0.4–1.3) for
men.
Figure 2 illustrates trends in the number of deaths
among PLHIV and their crude (all-cause) mortality
rates by treatment status. Before the roll-out of
ART in 2004, the mortality rates of PLHIV ranged
from 74 to 132 deaths per 1,000 pyo. The first clear
indications of a mortality decline among PLHIV are
visible in 2005, and by 2008 mortality rates had
dropped below 50 deaths per 1,000 pyo, both
among those who had initiated treatment and
among those for whom we do not have a record of
treatment initiation. Mortality continued to decline,
albeit more slowly, in the later years, decreasing in
2013 to 16.8 deaths per 1,000 pyo (95 per cent CI:
9.9–28.3) among PLHIV without a record of treat-
ment initiation and to 10.5 deaths per 1,000 pyo
(95 per cent CI: 4.4–25.3) among PLHIV who had
ever started ART.
The trend in the total number of deaths among
PLHIV corresponds to their mortality rates. In the
years preceding the introduction of ART, there
were between 65 and 117 deaths per year among
PLHIV. The number of deaths per annum started
declining in 2005, and by 2014 the annual death
count among PLHIV was around five.
Table 2 explores trends and sex differences in all-
cause mortality among PLHIV, and average model-
predicted mortality hazards are plotted in Figure
A1. The first column of data in Table 2 shows
results for the pre-ART period, while the second
and third columns show the coefficients for the
ART period. To allow for all two-way interactions
with treatment status, the model was fitted separately
for PLHIV who initiated treatment (the ‘treated’)
and those for whom we do not have a record of treat-
ment initiation (the ‘untreated’). In the pre-ART
period, the coefficient for males is less than one
and marginally significant, which suggests that the
mortality rates for men living with HIV in the year
2000 may have been lower than those for women.
However, this apparent mortality advantage among
Figure 2 Trends in the total number of deaths among PLHIV (left-hand axis) and all-cause mortality rates for
PLHIV (right-hand axis), by treatment status, Uganda 2000–14
Source: As for Figure 1.
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men quickly dissipated, as women exhibited a 22 per
cent decline in mortality hazard per calendar year
(hazard ratio (HR) = 0.78, 95 per cent CI: 0.69–
0.88) alongside no discernible change in mortality
risk across time for men (HR = 0.78 × 1.29 = 1.00,
95 per cent CI: 0.86–1.18) (Table 2). By 2003, the
mortality risks for women had dropped below those
of men (Figure A1). The large reduction in mortality
among HIV-positive women in the pre-ART period
may be partially attributable to small-scale roll-outs
of ART in 2001–03 by the private sector or non-gov-
ernmental organizations (NGOs) before RHSP
treatments started in 2004 (Wendo 2004), which
women may have benefited from more than men.
In comparison with the pre-ART period, mortality
decreased rapidly among PLHIV in the first decade
of ARTavailability. For women the greatest decrease
was observed in the first five years of ART avail-
ability (2004–08), while for men, the period in
which the rate of decrease was larger depended on
treatment status. During 2004–08, among untreated
PLHIV, the risk of mortality decreased by 28 per
cent per year for women (HR = 0.72, 95 per cent
CI: 0.67–0.77) and by 17 per cent per year for men
(HR = 0.72 × 1.15 = 0.83, 95 per cent CI: 0.77–0.89).
The mortality risk among PLHIV who ever started
ART decreased by 36 per cent per year among
women (HR = 0.64, 95 per cent CI: 0.57–0.71) and
by 13 per cent per year among men (HR = 0.64 ×
1.36 = 0.87, 95 per cent CI: 0.78–0.96) in the first
five years of ART availability.
From 2009 onwards, the risk of mortality
decreased significantly for untreated women, by
13 per cent per year (HR = 0.87, 95 per cent CI:
0.77–0.99), but did not decrease for untreated men
(HR = 0.87 × 1.08 = 0.94, 95 per cent CI: 0.84–1.05).
After 2008, no significant decrease was observed in
the mortality of women who ever initiated treatment
(HR = 0.96, 95 per cent CI: 0.79–1.16), while that of
men on ART decreased by 27 per cent per year
(HR = 0.96 × 0.76 = 0.73, 95 per cent CI: 0.59–0.90).
The more rapid decrease in mortality in the first
five years of ARTavailability among women reflects
the fact that the earlier ART programme focused on
treating the sickest individuals—those with lower
CD4 counts or clinical AIDS—whereas the later pro-
gramme initiated ART in asymptomatic individuals
at higher CD4 counts.
Table 2 All-cause mortality in HIV-positive individuals: hazard ratios and 95 per cent confidence intervals (Weibull
regression), Uganda 2000–14
Variables1
Pre-ART (2000–03)2
ART (2004–14)3
Untreated Treated
Calendar year (2000–03) 0.78 – –
(0.69–0.88) – –
Calendar year (2004–08) – 0.72 0.64
– (0.67–0.77) (0.57–0.71)
Calendar year (2009–14) – 0.87 0.96
– (0.77–0.99) (0.79–1.16)
Male4 0.65 0.93 0.93
(0.45–0.94) (0.76–1.14) (0.75–1.16)
Male × calendar year (2000–03) 1.29 – –
(1.05–1.57) – –
Male × calendar year (2004–08) – 1.15 1.36
– (1.04–1.28) (1.17–1.58)
Male × calendar year (2009–14) – 1.08 0.76
– (0.92–1.28) (0.57–1.01)
Weibull shape parameter (p) 1.90 1.79 1.75
(1.47–2.45) (1.47–2.18) (1.36–2.26)
Subjects 1,914 4,465 2,534
Deaths 349 645 431
1Estimates presented are hazard ratios from a Weibull regression model (with 95 per cent confidence intervals in parentheses). ‘Calendar
year’ refers to a per-year relative hazard in the period specified.
2In the pre-ART analysis, the year 2000 is the baseline calendar year.
3In the ARTanalysis, we use 2000–03 as the baseline calendar year (including all individuals/episodes regardless of ultimate treatment status)
for both untreated and treated analyses, and distinguish between untreated or treated episodes only from 2004–14. We do this to model the
trend in mortality rates by treatment status from when ARTwas first introduced in Rakai.
4Reference group is females.
Source: As for Table 1.
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Discussion
This rural Ugandan population experienced impor-
tant mortality reductions as a result of the expansion
of ART programmes. In the year 2000, the per capita
number of years lost to HIV in adulthood amounted
to 8.1 years for women and 4.3 years for men. By
2014, ten years after the roll-out of free ART, the
adult life-years deficits had shrunk to 1.3 and
0.4 years for women and men, respectively. Not all
of the progress is directly attributable to ART,
however, as evidenced by the fact that life-years
lived in adulthood started increasing before ART
became available in the study population. This
finding corroborates that from another study in
rural Uganda (Asiki et al. 2016). Because HIV inci-
dence in Uganda peaked in the early 1990s, we
would expect mortality to decline about ten years
later (i.e., just before the roll-out of ART). In the
RCCS, HIV incidence peaked in 2000 (at 1.3 per
100 pyo) and declined thereafter (Grabowski et al.
2017). This pattern contrasts with that seen in
South Africa, which experienced a later epidemic
and where the reversal in adult mortality did not
occur until ARTwas introduced (Reniers et al. 2017).
Among PLHIV, mortality rates gradually declined
after the roll-out of ART, both among those who had
started ART, and among men and women for whom
we did not have a record of treatment initiation. This
is likely due to two complementary factors. First,
some PLHIV may have received ART at health
facilities whose records could not be linked to the
demographic surveillance database. Second, the
pool of PLHIV who had not yet started ART will
have become increasingly healthier as a result of:
(a) the changes in October 2011 to the treatment
initiation thresholds from a CD4 cell count below
250 cells/μL to a count below 350 cells/μL; and (b)
the adoption in September 2012 of the ‘Option B+’
programme for prevention of mother-to-child trans-
mission, in which all HIV-positive pregnant women
received ART for life, irrespective of their CD4 cell
count.
Among PLHIV who had started ART, mortality
initially declined faster among women, which corrobo-
rates earlier evidence that women’s engagement with
health services was better than that of men. Women
are known to have higher HIV testing and counselling
and higher ART coverage rates (Muula et al. 2007;
Druyts et al. 2013; Staveteig et al. 2013), earlier treat-
ment initiation, and lower attrition and mortality rates
on ART (May et al. 2010; Hawkins et al. 2011; Mills,
Bakanda, Birungi, Chan, Hogg, et al. 2011; Cornell
et al. 2012; Auld et al. 2013; Druyts et al. 2013; Billioux
et al. 2017). In more recent years, however, mortality
amongmen with a record of ART initiation appears to
have decreased more rapidly, which suggests that they
are catching up.
Among PLHIV without a record of ART
initiation, the initial sex differences in mortality
were negligible, but the mortality risks declined
faster for women than for men once ART became
available. Again this serves as evidence that women
engage with HIV services earlier than men, a
phenomenon that may be reinforced by sex differ-
ences in HIV care and treatment eligibility as a
result of the programmes for the prevention of
mother-to-child transmission (Staveteig et al. 2013).
One important limitation of this study is that these
analyses have an upper age cut-off of 50 years. Some
HIV-associated mortality is likely to have occurred at
ages above 50, and this is particularly the case for
men, who are generally infected at older ages
(Gregson et al. 2002). In other words, the analyses
may underestimate the burden of HIV mortality
among older men, as well as the mortality reductions
this age group may have experienced.
Conclusions
Important mortality reductions have been experi-
enced by this rural Ugandan population. Mortality
declines began before the introduction of treatment,
as a result of historical declines in HIV incidence, and
steadily declined thereafter as a result of the expan-
sion of treatment programmes and treatment eligi-
bility criteria. Mortality among PLHIV initially
declined faster for women than for men, but the
latter appear to be catching up. As of 2014, the
residual burden of HIV mortality in adults under
age 50 is estimated to be 1.3 life-years (95 per cent
CI: 0.3–2.5) for women and 0.4 life-years (95 per
cent CI: −0.4–1.3) for men.
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